Overview

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection

Status:
Completed

Trial end date:
2012-01-01

Target enrollment:

Participant gender:

Summary

A Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects with Chronic Hepatitis C Virus Infection.

Phase:

Phase 1

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Antiviral Agents